Takeda Pharmaceutical (TAK) Notes Payables (2017 - 2018)
Takeda Pharmaceutical (TAK) posted quarterly Notes Payables of $3.3 billion for Q4 2018, up 19.65% year-over-year from $2.8 billion in Q4 2017, and up 19.65% quarter-over-quarter from $2.8 billion in Q4 2017.
Takeda Pharmaceutical (TAK) Notes Payables (2017 - 2018) Analysis & Trends
Takeda Pharmaceutical's Notes Payables history runs 2 years deep, the most recent figure standing at $3.3 billion for Q4 2018.
- In Q4 2018, Notes Payables rose 19.65% year-over-year to $3.3 billion; the TTM figure through Dec 2018 stood at $3.3 billion (up 19.65% YoY), while the FY2018 annual figure was $3.3 billion, up 19.65% from the prior year.
- Notes Payables for Q4 2018 stood at $3.3 billion, up from $2.8 billion in the prior quarter.
- The five-year high for Notes Payables was $3.3 billion in Q4 2018, with the low at $2.8 billion in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 3.34 Bn |
| Dec 31, 2017 | 2.79 Bn |